AstraZeneca Pharma India shares rise over 2% after CDSCO clears Imfinzi for new cancer use
AstraZeneca Pharma India
rose over 2% to Rs 9100 on BSE in Wednesday's trade after the company received regulatory approval for a new use of its
cancer therapy
Imfinzi.
On Tuesday,
AstraZeneca Pharma India
announced that it has received clearance from the Central Drugs Standard Control Organisation (CDSCO) to import durvalumab solution for infusion (brand name: Imfinzi) in 120 mg/2.4 ml and 500 mg/10 ml strengths for an additional indication.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Trekking pants for mountain sports and adventure travel
Trek Kit India
Shop Now
The
CDSCO approval
allows Imfinzi, in combination with carboplatin and paclitaxel, to be used as a first-line treatment for adults with primary, advanced, or recurrent endometrial cancer who are candidates for systemic therapy. The treatment will be followed by maintenance therapy using durvalumab and olaparib for patients with mismatch repair proficient (pMMR) endometrial cancer.
'This regulatory clearance enables AstraZeneca to market the approved formulation of Imfinzi in India for the specified indication, subject to other applicable statutory approvals,' the company said in a statement.
Impressive fourth-quarter earnings
Live Events
The regulatory development comes on the heels of a strong earnings report by AstraZeneca Pharma India. The company posted a 47.7% year-on-year jump in net profit to Rs 58.2 crore for the quarter ended March 2025, up from Rs 39.4 crore a year earlier.
Revenue for the quarter rose 25.4% to Rs 480.4 crore compared with Rs 383.2 crore in the same period last year, supported by "continued demand across its key therapy areas and improved market penetration".
Earnings before interest, tax, depreciation and amortisation (EBITDA) climbed 74.7% to Rs 86.3 crore, compared to Rs 49.4 crore a year ago. The EBITDA margin improved sharply to 17.96%, up from 12.89%.
The management attributed the robust financial performance to "continued investment in innovation and its portfolio of newer-generation therapies in the oncology, cardiovascular, and respiratory segments".
Stock performance and technical setup
On Tuesday, shares of AstraZeneca Pharma India closed at Rs 8,890 on the BSE, up by Rs 18.30 or 0.21%. The stock has gained 39.2% in the past year and 23.7% over the last six months. In the last three months, the shares are up nearly 5%, and have risen 11.6% in the past one month.
From a technical perspective, the stock is currently trading below its 10-day, 20-day, and 30-day simple moving averages (SMAs), but remains above its 5-day, 50-day, 100-day, 150-day, and 200-day SMAs.
The Relative Strength Index (RSI) stands at 45.7, suggesting neutral momentum. The Moving Average Convergence Divergence (MACD) is at 1.3, above the center line but below the signal line, indicating a potential pause in recent momentum.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Standard
15 minutes ago
- Business Standard
Market drop in early trade; breadth positive
Domestic equity benchmarks opened with modest losses on Friday, weighed down by global trade concerns after the United States imposed steep tariffs on several key trade partners and reaffirmed a 25% import duty on Indian goods. The Nifty traded below the 24,700 level. Pharma, metal and IT shares corrected, while FMCG and media shares advanced. At 09:30 IST, the barometer index, the S&P BSE Sensex declined 263.46 points or 0.32% to 80,922.12. The Nifty 50 index lost 77.10 points or 0.28% to 24,691.25. In the broader market, the S&P BSE Mid-Cap index slipped 0.34% and the S&P BSE Small-Cap index shed 0.02%. The market breadth was positive. On the BSE 1,756 shares rose and 1,182 shares fell. A total of 134 shares were unchanged. Foreign portfolio investors (FPIs) sold shares worth Rs 5,588.91 crore, while domestic institutional investors (DIIs) were net buyers to the tune of Rs 6,372.71 crore in the Indian equity market on 31 July 2025, provisional data showed. Stocks in Spotlight: Swiggy slipped 3.23% after the company reported consolidated net loss of Rs 1,197 crore in Q1 FY26 compared with net loss of Rs 606 crore in Q1 FY25. Revenue from operations jumped 53.97% YoY to Rs 4,961 crore in Q1 June 2025. Restaurant Brands Asia advanced 2.97% after the companys consolidated net loss narrowed to Rs 419.38 crore in Q1 FY26 compared with net loss of Rs 493.60 crore in Q1 FY25. Revenue from operations increased 7.89% YoY to Rs 697.72 crore during the quarter ended 30th June 2025. Coal India rose 0.54%. The companys consolidated net profit declined 20.19% to Rs 8,734.17 crore in Q1 FY26 compared with Rs 10,943.55 crore in Q1 FY25. Revenue from operations fell 5.39% YoY to Rs 35,482.19 crore in Q1 FY26. Numbers to Track: The yield on India's 10-year benchmark federal paper rose 0.03% to 6.378 from the previous close of 6.376. In the foreign exchange market, the rupee edged higher against the dollar. The partially convertible rupee was hovering at 87.4950 compared with its close of 87.6550 during the previous trading session. MCX Gold futures for 5 August 2025 settlement shed 0.19% to Rs 97,900. The US Dollar Index (DXY), which tracks the greenback's value against a basket of currencies, was up 0.09% to 99.83. The United States 10-year bond yield gained 0.41% to 4.378. In the commodities market, Brent crude for August 2025 settlement added 13 cents or 0.18% to $71.83 a barrel. Global Markets: Asian markets traded lower on Friday after U.S. President Donald Trump announced sweeping new tariffs on American trading partners, citing trade imbalances and national security concerns. The decision, signed late Thursday, is set to go into effect on 7 August and covers a wide range of goods from 69 countries and the 27-member European Union. Countries facing the highest rates include Syria at 41 percent, Switzerland at 39 percent, Laos and Myanmar at 40 percent, Iraq and Serbia at 35 percent, and Libya and Algeria at 30 percent. Others like Taiwan, India, and Vietnam fall in the 20 to 25 percent range. The European Union reached a deal under which goods with existing duty rates above 15 percent are exempt, while others will see adjusted levies. For countries not listed, a default rate of 10 percent will apply. Meanwhile, Japans unemployment rate was unchanged at 2.5% in June, from the previous month, government data released Friday showed. There were 122 job openings for every 100 job seekers in June, lower than the 124 openings for every 100 job seekers in the previous month. Stocks on Wall Street closed lower on Thursday, with the S&P 500 posting its third consecutive losing session. The broad market index fell 0.37% to settle at 6,339.39, while the Nasdaq Composite edged down 0.03% to 21,122.45. The Dow Jones Industrial Average declined 330.30 points, or 0.74%, closing at 44,130.98.
&w=3840&q=100)
Business Standard
15 minutes ago
- Business Standard
Shanti Gold International shares make positive debut; list at 15% premium
Shanti Gold IPO listing, Shanti Gold share price today: Shares of gold jewellery manufacturer and supplier Shanti Gold International made a positive D-Street debut on Friday, August 1, following the completion of its initial public offering (IPO). Shanti Gold shares listed at ₹229.10 on the BSE, marking a premium of ₹30.10 or approximately 15.13 per cent over the issue price of ₹199. On the National Stock Exchange (NSE), the shares debuted slightly lower at ₹227.55, reflecting a premium of ₹28.55 or around 14.35 per cent. Shanti Gold IPO listing fell short of the grey market estimates. Ahead of their D-Street debut, the unlisted shares of Shanti Gold were trading at ₹233 per share, reflecting a grey market premium (GMP) of ₹34 or 17.09 per cent over the issue price, according to sources tracking unofficial market activity. Shanti Gold IPO details The public offering of Shanti Gold comprised an entirely fresh issue of 18.1 million equity shares worth ₹360.11 crore, without any offer for sale (OFS) component. The public issue was offered at a price band of ₹189–199 per share, and a lot size of 75 shares. Shanti Gold was opened for subscription from July 25–29, 2025. It received an overwhelming demand from the investors and ended up getting oversubscribed by 81.17 times, riding on the back of the non-institutional investors (NIIs) who oversubscribed the category reserved for them by 151.48 times. This was followed by the qualified institutional buyers (QIBs) at 117.33 times, and retail investors at 30.37 times. The company proposes to utilise the proceeds from the public issue for funding capital expenditure requirements towards setting up of the proposed Jaipur facility. The company will further use the proceeds for funding working capital requirements of the company as well as for the repayment and/or pre-payment, in full or part, of certain borrowings availed by the company. The company will deploy the remaining amount for general corporate purposes. About Shanti Gold International Shanti Gold International is a manufacturer of high-quality 22kt CZ casting gold jewellery, in terms of installed production capacity, specializing in the design and production of all types of gold jewellery. The company offers a wide range of high-quality, intricately designed pieces, including bangles, rings, necklaces, and complete jewellery sets across various price points ranging from jewellery for special occasions, such as weddings, to festive and daily-wear jewellery.
&w=3840&q=100)
Business Standard
15 minutes ago
- Business Standard
PNB Housing Finance shares tank 15%; here's why investors are dumping stock
PNB Housing Finance shares slumped15 per cent, in the morning deals, on Friday, touching the lower band at ₹838.3 per share on BSE. At 9:28 AM, PNB Housing shares were trading 10 per cent lower at ₹887.6 per share. In comparison, BSE Sensex was down 0.2 per cent at 81,020.55. Why did PNB Housing Finance shares slip in trade? PNB Housing Finance shares were under pressure after MD & CEO Girish Kousgi resigned from his role effective October 28, 2025. The filing states that the reason for his stepping down is to pursue career aspirations outside the organisation. Kousgi is said to work closely with the board and senior management to ensure a smooth transition during this period. To elect a new MD & CEO, the board will initiate a rigorous, transparent and merit-based selection process. The board will immediately commence a search for a seasoned professional with proven expertise and industry experience, according to the filing. "We are confident of identifying a suitable professional soon, who will further accelerate our strategic direction and long-term value creation," said R. Chandrasekaran, chairman of the nomination and remuneration committee, board of directors, PNB Housing Finance. Post the resignation, the management said that it remains fully committed to executing its long-term strategy, underpinned by robust governance practices, prudent risk management, customer-centric approach, and sustainable growth initiatives. The board is confident that the company's high-performing team, which has been instrumental in delivering its strong performance, will continue to achieve the company's goals of robust growth, asset quality and margins. About PNB Housing Finance Limited PNB Housing Finance Limited is a deposit-taking housing finance company registered with the National Housing Bank (NHB). The company's asset base comprises primarily retail home loans. The retail business focuses on organised mass housing segment financing for the acquisition or construction of houses. In addition, it also provides loans against property and loans for purchase & construction of non-residential premises.
